Additional Risk Minimisation Measures

Introduction

All medicinal products carry risks. Most risks are managed through routine risk minimisation measures such as product information, prescribing information and package leaflets. In some situations, however, routine measures alone may be insufficient to ensure safe and effective use.

Additional Risk Minimisation Measures (aRMMs) are interventions intended to reduce the occurrence, severity or consequences of important risks. They are implemented when routine measures are considered inadequate to manage a particular safety concern.

Within a Risk Management Plan (RMP), Additional Risk Minimisation Measures are closely linked to Important Identified Risks, Important Potential Risks and, in some cases, areas of Missing Information.

The decision to implement additional measures should always be evidence-based, proportionate and scientifically justified.

Routine Versus Additional Risk Minimisation

Understanding this distinction is fundamental.

Routine Risk Minimisation Measures

Routine measures apply to most medicinal products.

Examples include:

• Summary of Product Characteristics (SmPC)
• Package leaflet
• Product labelling
• Contraindications
• Warnings and precautions
• Monitoring recommendations

These measures are considered part of normal product risk management.

Additional Risk Minimisation Measures

Additional measures are introduced when routine measures alone are unlikely to achieve the desired level of risk control.

The intervention should address a clearly defined safety concern.

Why Additional Measures Are Needed

Some risks require more than information in product literature.

Examples include:

• Severe teratogenicity
• Serious medication errors
• Complex monitoring requirements
• Risks requiring behavioural change
• Risks associated with inappropriate prescribing

In such situations, additional interventions may be required to influence healthcare professional or patient behaviour.

The objective is to reduce risk through improved awareness, monitoring or controlled use.

Fundamental Principle

Every Additional Risk Minimisation Measure should answer a specific question:

What safety problem are we trying to prevent or reduce?

The logic should be clear.

Important Risk
        ↓
Risk Minimisation Objective
        ↓
Additional Measure
        ↓
Expected Behaviour Change
        ↓
Risk Reduction

If this chain cannot be explained, the measure may be difficult to justify.

Common Objectives

Additional measures may seek to:

• Prevent exposure
• Improve patient selection
• Improve monitoring
• Improve recognition of adverse reactions
• Reduce prescribing errors
• Reduce administration errors
• Improve adherence to warnings

The objective should be defined before implementation.

Educational Materials

Educational materials are among the most common Additional Risk Minimisation Measures.

Examples include:

• Healthcare professional guides
• Prescriber checklists
• Pharmacist guides
• Patient brochures

Educational materials are intended to communicate important safety information beyond routine product literature.

They should focus on specific actions rather than general product information.

Prescriber Guides

Prescriber guides commonly address:

• Patient selection criteria
• Contraindications
• Monitoring requirements
• Risk factors
• Actions required when adverse events occur

The content should support safe prescribing decisions.

Patient Guides

Patient guides may address:

• Recognition of symptoms
• Monitoring requirements
• Situations requiring medical attention
• Safe use instructions

Patient materials should use language appropriate for the intended audience.

Patient Alert Cards

Patient alert cards are frequently used when rapid communication of safety information may be important.

Examples include:

• Immunosuppressive therapies
• Anticoagulants
• Teratogenic products

Cards may contain:

• Key safety messages
• Emergency information
• Monitoring recommendations

The objective is to ensure that important information remains readily available.

Pregnancy Prevention Programmes

Pregnancy Prevention Programmes (PPPs) represent one of the most intensive forms of Additional Risk Minimisation.

They are commonly used when exposure during pregnancy may result in serious fetal harm.

Programme components may include:

• Pregnancy testing
• Contraception requirements
• Prescriber certification
• Patient counselling
• Educational materials

The design should reflect the nature and severity of the risk.

Controlled Access Programmes

Controlled access systems restrict prescribing, dispensing or administration to defined conditions.

Examples may include:

• Certified prescribers
• Approved treatment centres
• Special registration programmes

These programmes are generally reserved for particularly serious risks.

Controlled Distribution Systems

Some products require restrictions on distribution channels.

Examples may include:

• Specialist pharmacies
• Restricted supply programmes
• Centralised dispensing systems

Such measures are usually implemented when conventional approaches are insufficient.

Laboratory Monitoring Programmes

Certain risks may require enhanced monitoring.

Examples include:

• Hepatic monitoring
• Haematological monitoring
• Renal monitoring
• Cardiac monitoring

The objective is early detection and intervention.

Monitoring requirements should be practical and proportionate.

Medication Error Prevention Measures

Risk minimisation may focus on preventing medication errors.

Examples include:

• Distinct packaging
• Administration guides
• Dosing calculators
• Educational materials

Medication error prevention is increasingly important for complex therapies.

Direct Healthcare Professional Communications

Direct Healthcare Professional Communications (DHPCs) may be used to communicate important new safety information.

Although DHPCs are not themselves long-term risk minimisation programmes, they often support implementation of risk minimisation activities.

They may accompany:

• New contraindications
• New warnings
• Major risk minimisation initiatives

Selecting Appropriate Measures

Selection should be driven by the nature of the risk.

Examples include:

Teratogenicity

Possible measures:

Pregnancy Prevention Programme

Serious Monitoring Requirement

Possible measures:

Prescriber Guide
Monitoring Checklist

Medication Error Risk

Possible measures:

Administration Guide
Patient Education

The intervention should address the underlying risk mechanism.

Proportionality

Additional measures should be proportionate.

Excessive interventions may:

• Reduce compliance
• Increase complexity
• Create unnecessary burden

Insufficient interventions may fail to manage important risks.

The goal is an appropriate balance.

Regulatory Commitments

Some Additional Risk Minimisation Measures become regulatory commitments.

These commitments may include:

• Educational programmes
• Pregnancy prevention activities
• Monitoring programmes
• Controlled access systems

Commitments require ongoing governance and maintenance.

Lifecycle Management

Additional measures should not continue indefinitely without review.

Possible outcomes include:

Retention

Measure remains necessary.

Modification

Content or implementation changes.

Expansion

Additional interventions introduced.

Discontinuation

Measure no longer justified.

Lifecycle decisions should be evidence-based.

Effectiveness Evaluation

Implementation alone is insufficient.

Regulators increasingly expect evidence that measures achieve their intended objectives.

Questions may include:

• Were materials distributed?
• Were materials received?
• Were messages understood?
• Did behaviour change?
• Was risk reduced?

These questions form the basis of effectiveness evaluation.

Process Indicators Versus Outcome Indicators

Two broad categories of evaluation exist.

Process Indicators

Examples:

• Distribution rates
• Training completion rates
• Programme participation

These evaluate implementation.

Outcome Indicators

Examples:

• Prescribing behaviour
• Monitoring compliance
• Exposure reduction
• Adverse outcome rates

These evaluate effectiveness.

Outcome indicators generally provide stronger evidence.

Common Regulatory Deficiencies

Recurring issues include:

Weak Justification

No clear rationale for the measure.

Excessive Complexity

Programmes become difficult to implement.

Poor Linkage to Safety Concerns

Measures are not connected clearly to identified risks.

Lack of Effectiveness Evaluation

Success cannot be demonstrated.

Failure to Update Materials

Educational content becomes outdated.

These deficiencies frequently attract regulatory attention.

Inspection and Audit Considerations

Inspectors may review:

• Scientific rationale
• Distribution records
• Training records
• Evaluation studies
• Governance processes
• Lifecycle management decisions

The key question is often:

Can the organisation demonstrate that the measure contributes to safer use of the product?

Role of the QPPV

The QPPV should understand:

• Major Additional Risk Minimisation Measures
• Associated safety concerns
• Regulatory commitments
• Effectiveness evaluation activities
• Significant programme changes

Inspectors frequently assess QPPV awareness of major product risk management strategies.

Characteristics of Effective Risk Minimisation Measures

Effective measures generally demonstrate:

• Clear objectives
• Appropriate targeting
• Practical implementation
• Strong scientific rationale
• Effective governance
• Demonstrable effectiveness

The objective is not simply to distribute information.

The objective is to reduce risk.

Key Takeaways

Additional Risk Minimisation Measures are implemented when routine measures are insufficient to manage important risks.

Examples include educational materials, patient alert cards, Pregnancy Prevention Programmes, controlled access systems and monitoring programmes.

Every measure should be linked to a defined safety concern and a clear risk minimisation objective.

Implementation alone is not sufficient; effectiveness should be evaluated wherever appropriate.

Successful risk minimisation programmes combine scientific justification, practical implementation and ongoing lifecycle management.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module V – Risk Management Systems.
2. EMA Guideline on Good Pharmacovigilance Practices.
3. CIOMS IX Practical Approaches to Risk Minimisation.
4. Commission Implementing Regulation (EU) No 520/2012.
5. EMA Risk Management Plan Template.
6. ICH E2E Pharmacovigilance Planning.
7. EMA Guidance on Risk Minimisation Measures.